Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab… February 18, 2018 Sihuan Pharma Opens Up R&D Shop in the San Francisco Bay Area August 14, 2017 AstraZeneca Investors Rejoice After COPD Drug Performs in Phase IV Study December 3, 2017
AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab… February 18, 2018
